Key Event Details

Sudarshan Pharma Industries Limited received formal approval from the National Stock Exchange of India Limited via letter reference NSE/LIST/78 dated October 23, 2026. The approval grants listing and admission to dealings on the NSE Capital Market Segment effective October 27, 2026, completing the migration process from the BSE SME Platform.

Share Capital Structure

The company's total equity share capital consists of 254,470,600 fully paid-up equity shares of Re. 1/- each. The shares will trade under the symbol SUDARSHAN and series EQ, with a market lot of 1 share.

Share Lock-in Details

The distinctive number breakdown reveals significant lock-in provisions:

  • 128,226,490 shares (distinctive numbers 1 to 128,226,490) are locked in until December 31, 2027
  • 9,000,000 shares (distinctive numbers 128,226,491 to 137,226,490) are locked in until February 20, 2028
  • 117,244,110 shares (distinctive numbers 137,226,491 to 254,470,600) are free from lock-in restrictions

Regulatory Compliance Requirements

The National Stock Exchange mandated that all future regulatory filings, reports, statements, and documents required under SEBI Regulations must be submitted exclusively through the NEAPS (NSE Electronic Application Processing System) portal at https://neaps.nseindia.com/NEWLISTINGCORP/. The exchange also introduced a NEAPS mobile application for listed entities to track submission status, access compliance calendars, and monitor stock performance.

Financial Reporting Obligations

The company is required to submit financial results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015, particularly if the migration occurred after the end of a quarter but on or before the due date for submission of financial results.

Correspondence Details

The disclosure references the company's previous communication dated May 21, 2026 (ref. no. SPIL/CS/SE/2026-2027/20) and was signed by the Company Secretary & Compliance Officer. The NSE approval letter was addressed to Mr. Nirav Kishor Shah, Company Secretary of Sudarshan Pharma Industries Limited, and signed by Snehal Mariappa, Manager at National Stock Exchange of India Limited.

#Tags: #SudarshanPharma #NSEListing #BSEMigration #Regulation30 #CorporateAction